- Lewis Chodosh, University of Pennsylvania
A combination of virtual screening and biochemical assays identified new small-molecule estrogen receptor inhibitors with the potential for use in novel endocrine-based therapies.
E2F4 transcription factor activity in tumors can be used to predict the survival outcomes of breast cancer patients, providing a prognostic molecular signature with potential for use across many clinical contexts.
Howell and colleagues from the BCC risk-and-prevention panel report on how adding new, but available, information to current risk models could ultimately better predict a woman’s individual breast cancer risk.
From the blog
Volume 16 Suppl 1 (3 November 2014)
Brighton, UK. 10-11 November 2014
Aims & scope
Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal publishes preclinical, translational and clinical studies with a biological basis, including Phase I and Phase II trials.
- 25 February 2015
- Breast cancer spread may be tied to cells that regulate blood flow
- 23 February 2015
- HER2-positive metastatic breast cancer: new standard of care
- 20 February 2015
- Cancer advances 'have benefited younger people more'
- 18 February 2015
- 'Puzzle': 35% of high-risk mastectomy patients get no RT